Bella Gindelsky is a distinguished Biopharmaceutical Program Manager at Biogen, specializing in gene therapy and biosimilar pipelines. With extensive experience spanning from 1992 at Tufts University to her current role, Bella has developed a robust expertise in early-, mid-, and late-stage drug and biologics development processes, chemical methodology, and protein analytics. She holds an MS in Biology and Biochemistry from Universitatea de Stat din Tiraspol and a Certification in Principles and Practices of Regulatory Affairs from Northeastern University.At Biogen, Bella has excelled in managing complex projects involving external partners, vendors, CMOs, and CROs, ensuring seamless collaboration with internal cross-functional teams. Her role involves strategic CMC advancements, optimizing business processes, and maintaining compliance with FDA guidance, ICH, and other quality standards. Bella is known for her organizational skills, ability to multitask in fast-paced environments, and fostering a culture of innovation. She has implemented significant improvements in gene therapy retain management and developed critical software to streamline workflow.Bella's career is marked by her commitment to excellence and innovation in biopharmaceutical program management, making her a key player in advancing therapeutic solutions that impact patient care globally.